Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats

Inflammation Research

Volumn 61, Issue 9, 2012, Pages 941-948

  Ossola, Cesar A ^a   Surkin, Pablo N ^a   Pugnaloni, Antonela ^a   Mohn, Claudia E ^a,b   Elverdin, Juan C ^a   Fernandez Solari, Javier ^a,b  

^a Department of Physiology   (Argentina)

^b Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

Author keywords

Bone injury; Lipopolysaccharide; Oxygen radicals; Prostaglandins; Tumor necrosis factor

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; METHANANDAMIDE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ALVEOLAR BONE LOSS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; GINGIVA; LONG TERM CARE; MALE; MANDIBLE; MAXILLA; MOLAR TOOTH; NONHUMAN; PERIODONTITIS; PROTEIN SYNTHESIS; RAT; TOOTH CERVIX;

ALVEOLAR BONE LOSS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACIDS; DINOPROSTONE; DISEASE MODELS, ANIMAL; LIPOPOLYSACCHARIDES; MALE; NITRIC OXIDE SYNTHASE TYPE II; PERIODONTITIS; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865131175     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0485-z     Document Type: Article

References (48)

1. Taubman MA, Valverde P, Han X, Kawai T. Immune response: the key to bone resorption in periodontal disease. J Periodontol. 2005;76:2033-41. (Pubitemid 41748950)
2. Prestifilippo JP, Carabajal E, Croci M, Fernández-Solari J, Rivera ES, Elverdin JC, Medina VA. Histamine modulates salivary secretion and diminishes the progression of periodontal disease in rat experimental periodontitis. Inflamm Res. 2012;61:455-61. doi:10.1007/s00011-011-0432-4.
3. Slomiany BL, Slomiany A. Porphyromonas gingivalis lipopolysaccharide- induced cytosolic phospholipase A2 activation interferes with salivary mucin synthesis via platelet activating factor generation. Inflammopharmacology. 2006;14:144-9. (Pubitemid 44358280)
4. Palsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, toll-like receptor-4. Immunology. 2004;113:153-62. (Pubitemid 39312442)
5. Amer M, Elverdin JC, Fernández-Solari J, Medina VA, Chiarenza AP, Vacas MI. Reduced methacholine-induced submandibular salivary secretion in rats with experimental periodontitis. Arch Oral Biol. 2011;56:421-7.
6. Tatakis DN. Interleukin-1 and bone metabolism: a review. J Periodontol. 1993;64:416-31. (Pubitemid 23208151)
7. Rink L, Kirchner H. Recent progress in the tumor necrosis factoralpha field. Int Arch Allergy Immunol. 1996;111:199-209. (Pubitemid 26345377)
8. Maia-Dantas A, Mohn CE, Burdet B, Zorrilla-Zubilete M, Mandalunis PM, Elverdin JC, Fernandez-Solari J. Ethanol consumption enhances periodontal inflammatory markers in rats. Arch Oral Biol. 2012;. doi:10.1016/j.archoralbio. 2012.02.008.
9. Offenbacher S, Heasman PA, Collins JG. Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J Periodontol. 1993;64:432-44.
10. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem. 1994;37:1889-93. (Pubitemid 24219781)
11. Yates ML, Barker EL. Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Mol Pharmacol. 2009;76:11-7.
12. Kupczyk P, Reich A, Szepietowski JC. Cannabinoid system in the skin-a possible target for future therapies in dermatology. Exp Dermatol. 2009;18:669-79.
13. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1:1333-49.
14. Mallat A, Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol. 2008;294:G9-12.
15. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis. 2009;33:57-71.
16. Izzo AA, Camilleri M. Cannabinoids in intestinal inflammation and cancer. Pharmacol Res. 2009;60:117-25.
17. Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol. 2008;20:69-74. (Pubitemid 351552679)
18. Kozono S, Matsuyama T, Biwasa KK, et al. Involvement of the endocannabinoid system in periodontal healing. Biochem Biophys Res Commun. 2010;394:928-33.
19. Llavaneras A, Ramamurthy NS, Heikkilä P, et al. A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxininduced periodontal breakdown in rats. J Periodontol. 2001;72:1069-77. (Pubitemid 32762869)
20. Gürkan A, Emingil G, Nizam N, Doǧanavşargil B, Sezak M, Kütükçüler N, Atilla G. Therapeutic efficacy of vasoactive intestinal peptide in escherichia coli lipopolysaccharide-induced experimental periodontitis in rats. J Periodontol. 2009;80: 1655-64.
21. Prestifilippo JP, Fernández-Solari J, Medina V, Rettori V, Elverdin JC. Role of the endocannabinoid system in ethanolinduced inhibition of salivary secretion. Alcohol Alcohol. 2009;44:443-8.
22. Prestifilippo JP, Fernández-Solari J, de la Cal C, Iribarne M, Suburo AM, Rettori V, McCann SM, Elverdin JC. Inhibition of salivary secretion by activation of endocannabinoid receptors. Exp Biol Med. 2006;231:1421-9. (Pubitemid 44330578)
23. Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, Makriyannis A. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem. 1998;41:5353-61. (Pubitemid 29031319)
24. Goutopoulos A, Fan P, Khanolkar AD, Xie XQ, Lin S, Makriyannis A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg Med Chem. 2001;9:1673-84. (Pubitemid 32651902)
25. Crawford JM, Taubman MA, Smith DJ. The natural history of periodontal bone loss in germfree and gnotobiotic rats infected with periodontopathic microorganisms. J Periodontal Res. 1978; 13:316-25. (Pubitemid 8347660)
26. Vacas MI, Amer M, Chiarenza AP, Luchelli MA, Mandalunis PM, Elverdin JC. Influence of submandibulectomy on alveolar bone loss in rats. J Periodontol. 2008;79:1075-80.
27. Bredt DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA. 1989;86:9030-3. (Pubitemid 20010361)
28. Mohn CE, Fernandez-Solari J, De Laurentiis A, Bornstein SR, Ehrhart-Bornstein M, Rettori V. Adrenal gland responses to lipopolysaccharide after stress and ethanol administration in male rats. Stress. 2011;14:216-26.
29. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, Kendall DA, Scammell BE, Reeve AJ, Chapman V. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10:R43.
30. Idris AI, Sophocleous A, Landao-Bassonga E, van't Hof RJ, Ralston SH. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology. 2008;149:5619-26.
31. Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J. Cannabinoids: novel medicines for the treatment of Huntington's disease. Recent Pat CNS Drug Discov. 2012;7:41-8.
32. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72:735-44.
33. Nakajima Y, Furuichi Y, Biswas KK, Hashiguchi T, Kawahara K, Yamaji K, Uchimura T, Izumi Y, Maruyama I. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. FEBS Lett. 2006;580:613-9. (Pubitemid 43089695)
34. Preshaw PM, Heasman PA. Prostaglandin E2 concentrations in gingival crevicular fluid: observation in untreated chronic periodontitis. J Clin Periodontol. 2002;29:15-20. (Pubitemid 41697729)
35. Ekuni D, Endo Y, Irie K, Azuma T, Tamaki N, Tomofuji T, et al. Imbalance of oxidative/anti-oxidative status induced by periodontitis is involved in apoptosis of rat submandibular glands. Arch Oral Biol. 2010;55:170-6.
36. Scannapieco FA, Dasanayake AP, Chhun N. Does periodontal therapy reduce the risk for systemic diseases? Dent Clin N Am. 2010;54:163-81.
37. Fowler EB, Breault LG, Cuenin MF. Periodontal disease and its association with systemic disease. Mil Med. 2001;166:85-9. (Pubitemid 32097113)
38. Lappin DF, Kjeldsen M, Sander L, Kinane DF. Inducible nitric oxide synthase expression in periodontitis. J Periodontal Res. 2000;5:369-73.
39. Brandi ML, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross SS, Polak JM, MacIntyre I. Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci USA. 1995;92:2954-8.
40. Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N. Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res. 1995;10:1040-9.
41. Karmaus PW, Chen W, Crawford RB, Harkema JR, Kaplan BL, Kaminski NE. Deletion of cannabinoid receptors 1 and 2 exacerbates APC function to increase inflammation and cellular immunity during influenza infection. J Leukoc Biol. 2011;90:983-95.
42. Darling MR, Arendorf TM. Review of the effects of cannabis smoking on oral health. Int Dent J. 1992;42:19-22.
43. Nogueira-Filho GR, Todescan S, Shah A, Rosa BT, Tunes Uda R, Cesar Neto JB. Impact of cannabis sativa (marijuana) smoke on alveolar bone loss: a histometric study in rats. J Periodontol. 2011;82:1602-7.
44. Pertwee RG. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed. 1999;6:12-5.
45. Walker JM, Strangman NM, Huang SM. Cannabinoids and pain. Pain Res Manag. 2001;6:74-9. (Pubitemid 32780609)
46. Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol. 2011;203:75-104.
47. Kurzthaler I, Hummer M, Miller C, Sperner-Unterweger B, Günther V, Wechdorn H, Battista HJ, Fleischhacker WW. Effect of cannabis use on cognitive functions and driving ability. J Clin Psychiatry. 1999;60:395-9. (Pubitemid 29289728)
48. Lutz B. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol. 2004;68:1691-8. (Pubitemid 39278491)